Albumin, widely recognized as a highly sensitive and specific marker of hepatocellular carcinoma (HCC), is currently unavailable in the diagnostic laboratory because of the lack of a robust platform. In a prior study we detected albumin mRNA in the majority of intrahepatic cholangiocarcinomas using a novel branched chain RNA in situ hybridization (ISH) platform. We now explore the utility of albumin ISH as a marker of hepatocellular differentiation in HCCs, and compare its sensitivity with Hep Par 1 and Arginase-1. We evaluated 93 HCCs and its mimics including neuroendocrine tumors of the gastrointestinal tract (n = 31), neuroendocrine tumors of the pancreas (n = 163), melanoma (n = 15), and gallbladder carcinoma (n = 34). We performed ISH for albumin and immunohistochemistry for Hep Par 1 and Arginase-1. Five previously uncharacterized hepatic neoplasms from our files were also evaluated. Immunohistochemistry for Arginase-1 was performed on 59 intrahepatic cholangiocarcinomas. In addition, 43 HCCs evaluated on the manual platform were also examined on the automated instrument. Fifty-five percent of HCCs were moderately differentiated and 39% poorly differentiated. The sensitivity of ISH for albumin was 99%, with 92 of 93 HCCs staining positive for albumin. In contrast to ISH, the sensitivity of immunohistochemistry for Hep Par 1 and Arginase-1 was 84% and 83%, respectively. The sensitivity of albumin for poorly differ-entiated HCCs was 99%, whereas that for Arginase-1 and Hep Par 1 was 71% and 64%, respectively. Ninety-seven percent of the HCCs showed albumin positivity in >50% of tumor cells using the ISH platform, as compared with 76% and 70% for Hep Par 1 and Arginase-1 immunohistochemistry, respectively. Three of the 5 previously uncharacterized neoplasms were positive for albumin ISH. Automated albumin ISH platform performed equivalently to the manual format, with albumin reactivity in >50% of tumor cells in all 43 cases that were tested on both platforms. All non-HCCs were negative for albumin. All 59 intrahepatic cholangiocarcinomas were negative for Arginase-1. In conclusion, branched chain ISH performed on manual and automated mode is a robust assay for detecting albumin with sensitivity for poorly differentiated HCCs superior to Arginase-1 and Hep Par 1. When interpreted in conjunction with Arginase-1, albumin ISH offers a high level of sensitivity and specificity.
H epatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. 1 The immunohistochemical diagnosis of poorly differentiated and undifferentiated HCC has traditionally been difficult because of a lack of a reliable marker of hepatocellular differentiation. 2, 3 Alpha fetoprotein (AFP) and polyclonal carcinoembryonic antigen (CEA) were the first of many markers of hepatocellular differentiation that have emerged in the last 4 decades (Table 1) . However, sensitivity of these markers is low-AFP ranges from 30% to 50% and polyclonal CEA from 60% to 90%. 13 Background staining can make these markers difficult to interpret, and, furthermore, they are more likely to be negative in poorly differentiated and undifferentiated carcinomas. 2, 3 Hep Par 1, a sensitive marker of hepatocellular differentiation represents a significant advance over prior assays. [2] [3] [4] 13 The bright granular cytoplasmic reactivity made interpretation relatively easy, and thus it quickly emerged as the "go to" marker for hepatocellular differentiation. With its widespread adoption, 2 conspicuous failings emerged 6 : (1) The specificity, with a significant percentage of gastric, esophageal, and lung adenocarcinomas, shows strong reactivity, a particularly troubling finding, as these tumors frequently metastasize to the liver; (2) The sensitivity, especially for poorly differentiated HCCs, which were significantly lower than for well-differentiated tumors, thus limiting its diagnostic value.
More recently, Arginase-1, an enzyme involved in the hydrolysis of arginine to ornithine and urea, was recognized as a sensitive and specific marker for benign and malignant hepatocytes. 9, 14 Subsequent studies have validated its high sensitivity and specificity, as well as its value in evaluating poorly differentiated HCCs. [7] [8] [9] [14] [15] [16] Nevertheless, as evidenced in this study, the sensitivity of Arginase-1 in poorly differentiated HCCs is imperfect, and it is in this category that ancillary support is often required to bolster a diagnosis of HCC.
Albumin, a protein synthesized by hepatocytes, was first proposed as a marker of hepatocellular differentiation in the late 1980s. 5 However, immunohistochemical detection of albumin proved difficult primarily because of its ubiquitous presence, a problem easily overcome by detecting mRNA instead of protein. [10] [11] [12] [13] 17, 18 However, despite the fact that albumin has the potential to be a highly sensitive and specific marker for HCC, it has not found widespread use in the diagnostic laboratory, driven by 2 unresolved problems: (1) the theoretical possibility that mRNA degrades far more quickly than proteins, and hence an mRNA-based biomarker is likely to be less sensitive than immunohistochemistry; and (2) lack of a robust and sensitive automated platform for the detection of RNA that could be adapted for the clinical laboratory.
The introduction of a branched chain in situ hybridization (ISH) assay addresses one of the issues-the assay achieves a high level of sensitivity by amplifying the RNA signal. We have recently utilized this approach for the diagnosis of intrahepatic cholangiocarcinoma, 19 wherein albumin ISH serves as an indicator of hepatic origin. In this study, we compare albumin with the 2 leading markers of hepatocellular differentiation-Arginase-1 and Hep Par 1-when used for the diagnosis of HCC in formalin-fixed biopsy material. We also assess an automation platform for the detection of albumin mRNA that would potentially allow the adoption of this technology in routine pathology practice.
MATERIALS AND METHODS

Case Selection
The study cases were selected on the basis of a search of the pathology database at the Massachusetts General Hospital from 2003 through 2013. The study was approved by the Institutional Review Board at the Massachusetts General Hospital.
Hepatocellular Carcinomas
Tissue microarrays from 94 HCCs were constructed. The arrays were composed of 3 mm cores of paraffin-embedded tissue. Moderately and poorly differentiated HCCs were overrepresented in this cohort. Other than 3 tumors that showed clear cells, the other cases represented conventional HCCs. Expression of Arginase-1 and Hep Par 1 was examined on an immunohistochemical platform, whereas that for albumin was on an ISH platform-ViewRNA (Affymetrix, Santa Clara, CA) (see below for details). The HCCs were graded as well, moderate, and poorly differentiated. 20 The original diagnosis of poorly differentiated HCC was based on the histologic features, specifically the lack of evidence of cholangiocellular differentiation, supplemented in selected cases by the use of immunohistochemistry. The cirrhotic environment within which these tumors arose provided additional support to the diagnosis. Twenty-two examples of benign liver adjacent to the tumor were also evaluated for albumin; 14 cases showed cirrhosis.
Three hepatoid carcinomas, 1 each from the ovary, stomach, and pancreas, were also evaluated. Six additional examples of HCC from 2 institutions (UCSF and VA Medical Center, San Francisco, CA and University Hospital Southampton NHS Foundation Trust, Southampton, UK) were also evaluated. Entire sections were evaluated on these cases, as well as the hepatoid carcinomas. Arginase-1 8, 9 Enzyme involved in the hydrolysis of arginine to ornithine and urea 96% Rare 86 ISH albumin [10] [11] [12] Major protein in serum > 95% None > 95%
Intrahepatic Cholangiocarcinomas
A total of 59 resected intrahepatic cholangiocarcinomas were tested for Arginase-1. These tumors have been previously tested by albumin ISH. 19 The intrahepatic cholangiocarcinomas were distinguished from perihilar adenocarcinomas on the basis of the epicenter of the lesion, as determined by imaging, gross, and microscopic evaluation. The tumors were placed on tissue microarrays composed of 3 mm cores of tissue.
Uncharacterized Tumors
We examined 5 hepatic neoplasms over a 5-year period from the institutional files of one of the authors (V.D.) that were classified as undifferentiated carcinomas and lacked histologic and immunohistochemical evidence of hepatocellular differentiation. Entire sections were examined for albumin in this class of tumors.
Nonhepatic Tumors
We examined mimics of HCC including neuroendocrine tumors of the gastrointestinal tract (n = 31), neuroendocrine tumors of the pancreas (n = 163), melanoma (n = 15), and gallbladder carcinoma (n = 34). The tumors were placed on tissue microarrays composed of 3 mm cores of tissue.
Immunohistochemistry
Immunohistochemical analysis for Hep Par 1 (Dako; 1:25; retrieval EDTA pH 9.0 for 20 min) and Arginase (Cell Marque; 1:600; retrieval citrate pH 6.0 for 30 min) was performed. Details of the procedure are provided in a prior publication from this institution. 21 In Situ Hybridization ISH was performed using both the manual and automated ViewRNA platform (Affymetrix), and results were compared when indicated. This technology utilizes a branched DNA structure for signal amplification to enable detection of RNA in formalin-fixed paraffin-embedded tissue. Briefly, multiple tiling probes for a gene are hybridized to a specific target RNA. A signal amplification structure is created by a series of hybridization steps in which a preamplifier (Pre-AMP) molecule hybridizes to each oligonucleotide probe pair, multiple amplifier (AMP) molecules hybridize to each pre-AMP, and multiple alkaline phosphatase-conjugated label probes hybridize to each AMP (Supplementary material 1, Supplemental Digital Content 1, http://links.lww.com/PAS/A244). The branched structure has approximately 400 binding sites for the alkaline phosphatase-labeled probe, which can then be visualized with the fast-red substrate as a chromogen to form a red dot or diffuse precipitate that allows the detection of RNA transcripts in situ.
ISH probe (Affymetrix) was designed against albumin transcripts as identified in the NCBI nucleotide database (Supplementary material 2, Supplemental Digital Content 2, http://links.lww.com/PAS/A245). Formalinfixed paraffin-embedded tissues were sectioned at 5 ± 1 mm thickness and mounted on Surgipath X-tra glass slides (Leica BioSystems, Buffalo grove, IL), baked for 1 hour at 601C to ensure tissue attachment to the glass slides, and stored at À 801C until ready for ISH staining. ISH was performed in the manual and automated formats as described below.
Manual ISH Assay
For the manual (nonautomated) format for ISH, baked tissue sections were subjected to xylene deparaffinization, followed by ethanol dehydration. To unmask the RNA targets, dewaxed sections were incubated in 500 mL pretreatment buffer at 90 to 951C for 10 minutes and digested with 1:100 dilution protease at 401C for 10 minutes, followed by fixation with 10% neutral buffered formalin at room temperature for 5 minutes. Unmasked tissue sections were subsequently hybridized with 1:50 dilution of the albumin probe set for 2 hours at 401C, followed by a series of posthybridization washes. Signal amplification was achieved by a series of sequential hybridizations and washes as described in the user manual (see below). The specific conditions were as follow: pre-AMP: 25 minutes at 401C; AMP: 15 minutes at 401C; hybridization with labeled probe: 1:1000 dilution for 15 minutes at 401C; signal detection with fast-red substrate: 30 minutes at 401C. Slides were postfixed in 10% neutral buffered formalin, counterstained with Gill hematoxylin, mounted using Dako Ultramount (Dako, Carpinteria, CA), and visualized using a standard bright-field microscope. Additional details of the assay are provided at http://www.panomics.com/downloads/17400RevF%20140822 _ViewRNA%20ISH%20Tissue%201-Plex.pdf.
Automated Albumin ISH Assay
A total of 43 cases evaluated on the manual assay were repeated on the automated platform. In 20 cases, entire sections were evaluated, whereas 3 mm microarray samples were evaluated in the other 23 cases.
The albumin probe used in the automated assay was identical to that used in the manual assay. Automated ISH assays for albumin mRNA were performed using View-RNA eZ Detection Kit (Affymetrix) on the Bond RX immunohistochemistry and ISH Staining System with BDZ 6.0 software (Leica Biosystems). Paraffin-embedded tissue sections on slides were processed automatically from deparaffinization, through ISH staining to hematoxylin counterstaining; sections were coverslipped off-instrument. Briefly, 5-mm-thick sections of formalin-fixed tissue were baked for 1 hour at 601C and placed on the Bond RX for processing. The Bond RX user-selectable settings were as follows: ViewRNA 1 protocol; ViewRNA Dewax1; View-RNA HIER 10 minutes, ER1 (95); ViewRNA Enzyme1 (20) ; ViewRNA Probe Hybridization. With these settings, the RNA unmasking conditions for the liver tissue consisted of a 10-minute incubation at 951C in Bond Epitope Retrieval Solution 1 (Leica Biosystems), followed by 20-minute incubation with Proteinase K from the Bond Enzyme Pretreatment Kit at 1:1000 dilution (Leica Biosystems). Human albumin (Cat#ZVA1-16742) and housekeeping mRNA-targeting probe sets composed of a cocktail of GAPDH, PPIB, and ACTB were diluted 1:20 in ViewRNA Probe Diluent (Affymetrix); the housekeeping gene sets were evaluated in selected cases. Postrun, slides were rinsed with water, air dried for 30 minutes at room temperature, dipped in xylene, and mounted using Histo-Mount solution (Life Technologies, Grand Island, NY). Additional details on the automation are provided at http:// www.panomics.com/downloads/15891_RevC%20140910_ ViewRNA%20eZ%20Assay%20Manual_Compressed.pdf Quantification A semiquantitative method of scoring was devised and used to score both immunohistochemistry and ISH. The quantitative analysis was performed only on the tumor tissue samples on the microarray. Tumors demonstrating no staining at all were given a score of 0, <5% of cells staining-score 1+, 5% to 50%-score 2+, and >50%-score 3.
RESULTS
Albumin (ISH) Normal Liver
Similar to a prior study, the 22 examples of benign liver (14 with cirrhosis) tissue adjacent to the HCCs were diffusely positive for albumin. 19 Periportal hepatocytes stained more intensely than zone 3 hepatocytes. Whereas the interlobular bile ducts were occasionally positive, bile ductules were uniformly positive for albumin.
Hepatocellular Carcinoma
In order to determine the utility of albumin ISH for the diagnosis of HCC we tested a cohort of 94 additional HCC cases selected for a wide range of hepatocellular differentiation. The mean age of the cohort of patients with HCC was 64 years (range, 44 to 81 y), with 65 men and 28 women. The majority of the HCCs were moderately differentiated (55%) or poorly differentiated (39%). The background liver showed cirrhosis in 83 cases.
Ninety-two of 94 HCCs were positive for albumin ( Figs. 1-3 ; Table 2 ). One of the tumors negative for albumin failed GAPDH testing and was not included in the final analysis. The suboptimal mRNA preservation was likely related to radiofrequency ablation. Among the positive cases, 89 cases showed reactivity in >50% of the tumor, and all 92 cases showed characteristic dot-like reactivity in > 5% of the tumor cells. All 3 examples of HCC with clear cells were positive for albumin with >50% of the tumor positive in all 3 cases. We also evaluated 6 additional HCCs from 2 other institutions, all of which were diffusely positive for albumin. Five of these tumors were poorly differentiated and 1 moderately differentiated.
In radiofrequency ablated tumors, the necrotic regions of tumor, both foci of coagulated and liquifactive necrosis, were negative for albumin. The adjacent foci of viable tumor were strongly positive for albumin. In addition, tissues demonstrating visible electrothermy artifact showed considerable decrease in the intensity of reactivity for albumin.
Comparison of ISH Albumin With Immunohistochemistry for Hep Par 1 and Arginase-1
In addition to the presence or absence of reactivity, a semiquantitative analysis was performed to document the percentage of tumor cells staining on each preparation. The semiquantitative analysis was performed only on the tissue microarray samples of HCC.
Hep Par 1 (Immunohistochemistry)
Seventy-five of the 89 HCCs were positive for Hep Par 1. The sensitivity of the assay was 84%. Seven of the 75 (9%) positive cases showed focal (1+) reactivity. Among the 14 tumors negative for Hep Par 1, 1 was moderately differentiated and 13 poorly differentiated.
Arginase-1 (Immunohistochemistry)
Seventy-two of the 87 HCCs were positive for Arginase-1; sensitivity of the assay was 83%. Eleven (15%) tumors that were positive for Arginase-1 were only focally (1+) positive. Among the 15 tumors negative for Arginase-1, 5 were moderately differentiated and 10 poorly differentiated.
Albumin (ISH) Versus Hep Par 1 and Arginase-1 (Immunohistochemistry)
The only HCC (poorly differentiated) that was negative for albumin was positive for both Hep Par 1 and Arginase-1. The 9 tumors that were negative for both Hep Par 1 and Arginase-1 were positive for albumin; 8 of these tumors were grade 3.
Hepatoid Carcinoma
Although not the primary focus of this paper, we evaluated 3 cases of hepatoid carcinomas, 1 each from the ovary, pancreas, and the stomach, all of which showed diffuse positivity using albumin ISH. In comparison, 2 of the 3 tumors were positive for Hep Par 1, whereas all of the 3 tumors were negative for Arginase-1. The one tumor (pancreas) that was negative for Hep Par 1 showed diffuse strong positive staining using AFP immunohistochemistry ( Fig. 4 ).
Intrahepatic Cholangiocarcinomas
The mean age of this cohort was 64 years (range, 37 to 77 y; M:F = 1:1). The median tumor size was 5.5 cm. We previously found these tumors to be positive for albumin ISH. 19 The 59 tumors were evaluated on an immunohistochemical platform for Arginase-1, and 1 was found to be positive for this marker.
Automated Platform
In order to assess the utility of albumin ISH for routine pathology practice, 43 HCCs (26 moderate and 17 poorly differentiated) that stained positive for albumin using the manual ISH platform were retested on the automated Leica Bond RX platform. Using the manual staining platform, all cases had shown albumin ISH staining in >50% of the tumor component. Albumin ISH using the automated platform showed a similar staining pattern to what was seen using the manual platform for all tested cases, and the concordance between the 2 platforms was 100%.
Specificity of Albumin as a Marker of Hepatocellular Differentiation
We further evaluated cases that could potentially mimic HCC, including neuroendocrine tumors of the gastrointestinal tract, neuroendocrine tumors of the pancreas, melanoma, and gallbladder carcinoma (n = 143). These tumors were uniformly negative for albumin.
Difficult to Characterize Hepatic Neoplasms
Of the 5 undifferentiated tumors, 3 were positive for albumin ( Fig. 5 ; Table 3 ). One of the cases negative for ISH was eventually diagnosed as gallbladder carcinoma. The biopsy from case 3 was largely necrotic tissue; the rare viable cells were negative for albumin. In retrospect, the presence of Arginase-1 (in 1 case) and an elevated AFP level in all 3 cases support the diagnosis of HCC.
DISCUSSION
The 2 common challenges encountered by the pathologist evaluating a hepatic neoplasm are: (1) the distinction between a benign and malignant hepatic neoplasm; and (2) at the poorly differentiated/undifferentiated end of the spectrum, distinguishing HCCs from metastatic adenocarcinoma. There are a wide variety of markers that assist in unraveling the latter diagnostic problem including AFP, polyclonal CEA, CD10, Hep Par 1, and Arginase-1 (Table 1) .
Among these, Arginase-1 has emerged as the marker of choice-its high sensitivity for hepatocellular differentiation combined with the virtual absence of reactivity of nonhepatic neoplasms makes it an almost ideal marker. 14 Importantly, Arginase-1 also offers a high sensitivity for poorly differentiated HCC-86% in a recent analysis. 14 In that study, Arginase-1 outperformed Hep Par 1 with an overall sensitivity of 96% and specificity of 84%, respectively. 14 Among poorly differentiated HCCs, however, the 2 stains may prove complimentary, as a significant percentage of HCCs negative for Arginase-1 were positive for Hep Par 1.
Our study suggests that albumin ISH offers sensitivity for poorly differentiated HCC superior to Arginase-1. A higher percentage of tumor cells were positive for albumin. In addition, almost a fifth of the tumors that were positive for Arginase-1 showed only faint reactivity for this protein. In our experience this low-intensity reactivity is often best regarded as equivocal evidence of hepatocellular differentiation. The red dot-like staining pattern makes the ISH assay easier to interpret than immunohistochemistry. The interpretation was further Hep Par 1 + (N = 89) Arginase + (N = 87) %+ Score 0 Score 1 Score 2 Score 3 %+ Score 0 Score 1 Score 2 Score 3 %+ Score 0 Score 1 Score 2 Score 3   All cases  99  1  0  3  89  84  14  7  8  60  83  15  11  18  43  Grade 1 100  0  0  0  6  100  0  0  0  4  100  0  1  2  1  Grade 2 100  0  0  1  50  98  1  5  4  39  90  5  5  11  27  Grade 3  99  1  0  2  33  64  13  2  4  17  71  10  5  5  15 Score 1 = < 5% of tumor staining positive. Score 2 = 5% to 50% of tumor staining positive. Score 3 = > 50% of tumor staining positive. Albumin was evaluated using ISH.
Hep Par 1 and Arginase-1 was evaluated on an immunohistochemistry platform. bISH indicates branched chain ISH; grade, grade of differentiation. simplified by the virtual absence of a nonspecific signal. It should be noted that this analysis was performed on routinely processed paraffin-embedded tissue, and there were no specific efforts to ensure preservation of RNA. Poorly differentiated hepatocellular neoplasms were overrepresented in this cohort, constituting 39% of cases. This was deliberately done to test the assay on a cohort of cases most likely requiring the use of ancillary testing. Within the class of poorly differentiated HCCs, all but 1 poorly differentiated HCC stained positively for albumin. In comparison, 71% and 64% of poorly differentiated HCCs stained for Arginase-1 and Hep Par 1, respectively.
Graham et al, 22 using a platform that is likely similar to that presented in this study, found similar results with majority of the HCCs being positive for albumin. However, the results of this study, published only in an abstract form, found the sensitivity of Arginase-1 and albumin to be comparable. The reason underlying these differences is uncertain, particularly as technical details are unavailable. 22 In conjunction with a recent study on intrahepatic cholangiocarcinomas by our group, 22 we confirm that the increased sensitivity of the ISH assay does not lead to a loss of specificity, and a diverse group of carcinomas including those arising from the lung, breast, esophagus, stomach, colon, ovary, renal cell carcinoma, and urinary bladder lacked reactivity for albumin. 19 Other potential mimics of HCC tested in the present study, including melanoma and neuroendocrine tumors, were also negative for albumin. However, albumin reactivity does not distinguish between HCC and cholangiocarcinoma; on the basis of our data the majority of intrahepatic cholangiocarcinomas are also positive for albumin, albeit at a lower intensity. 19 Arginase-1 appears to represent a more specific marker for distinguishing HCC from cholangiocarcinoma; however, occasional cholangiocarcinomas were positive in our study (1 of 59 cases) and in other studies (2 of 18 cases). 8, 14 Another potential application of the assay is the diagnosis of hepatoid carcinomas. The current ancillary tests for the diagnosis of hepatoid carcinoma is far from satisfactory; Arginase-1 is generally negative, whereas Hep Par 1 lacks the required specificity to distinguish between adenocarcinomas and hepatoid carcinomas. 8, 16 Nevertheless, a larger cohort of hepatoid carcinomas must be analyzed before using albumin as a definitive marker of hepatoid carcinoma. Although we did not stain examples of hepatocellular dysplasia and hepatic adenomas, we anticipate that these neoplasms, like all neoplasms with evidence of hepatocellular differentiation, would stain positively for albumin. Thus, this assay cannot distinguish HCC from adenoma and hepatic dysplasia.
Our results are similar to prior efforts at detecting albumin in hepatic neoplasms. [10] [11] [12] [13] 17, 18, 23 The current ISH platform, however, differs considerably from the albumin ISH assay introduced in the 1990s. In this prior assay, oligonucleotide probes were labeled with digoxigenin, whereas the current assay amplifies the mRNA signal using branched DNA amplification, theoretically allowing for the detection of a single copy of RNA and considerably increasing the sensitivity of the assay. Although high sensitivity for HCC can be achieved with traditional ISH assays (93% to 95%), 10, 12, 13 difficulties of implementing and automating this technique have prevented its wide acceptance. As demonstrated in this study, a branched chain ISH approach can be readily automated and detects albumin in poorly differentiated cases. Signal amplification provides a means of uncovering albumin expression at low levels and accounts for the almost perfect sensitivity of the current assay. [10] [11] [12] 24 We validate our findings by evaluating a cohort of poorly differentiated/undifferentiated carcinomas of the liver. The 5 cases that lacked unequivocal histologic or immunohistochemical evidence of hepatocellular differentiation were identified in the files of one of the authors (V.D.). Three of the 5 cases were strongly (> 50% tumor cells stained) positive for albumin (although in retrospect Arginase-1 was positive in 1 case). Case number 2 represented a gallbladder carcinoma and was negative for albumin. However, the possibility that some of these tumors represent an undifferentiated hepatic tumor that does not display hepatic differentiation (such as a cholangiocarcinoma) cannot be excluded, although this is unlikely given the markedly elevated AFP level.
The ISH platform used here offers pathologists a novel means of detecting mRNA, including targets that are expressed at low levels. The availability of this technology is particularly valuable for detecting secreted proteins such as albumin, as well as targets against which an immunohistochemical approach has been unsuccessful. The bright red dots generated by this technology make the assessment of these preparations straightforward. It should be emphasized that the presence of even rare dots (> 3 per cell) is strong evidence of a positive result, as a nonspecific signal (in our experience <1 dot per 10 cells) is minimal.
To conclude, branched chain albumin ISH offers a robust means of detecting a tumor of liver origin and is particularly valuable when confronted with a poorly differentiated HCC. However, the assay cannot distinguish HCCs from intrahepatic cholangiocarcinomas. The combined use of albumin and Arginase-1 could represent a powerful means of identifying tumors with hepatocellular differentiation; with tumors that are positive for albumin but lacking Arginase-1, a careful evaluation of the morphologic features is necessary to exclude an intrahepatic cholangiocarcinoma. The ability to automate the assay opens up the prospect of its use in the diagnostic clinical laboratory.
